Feiyang Liu

发表

Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons

Luyong Zhang, Tao Pang, H. Liao, 2013, Neuroscience Letters.

A glycosylation strategy to develop a low toxic naphthalimide fluorescent probe for the detection of Fe3+ in aqueous medium.

Ruihua Ding, Jianyi Wang, Mian Wang, 2017, Dalton transactions.

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

N. Gray, Qingsong Liu, D. McMillin, 2014, ACS chemical biology.

Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.

Qingsong Liu, C. Yun, Zhenquan Hu, 2018, European journal of medicinal chemistry.

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.

Zhenquan Hu, Q. Liu, Hong Wu, 2018, European journal of medicinal chemistry.

Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences

C. Liang, Liangdan Sun, Qingsong Liu, 2020, Molecular Biomedicine.

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

N. Gray, Qingsong Liu, C. Mitsiades, 2013, PloS one.

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Qingsong Liu, C. Yun, Zhenquan Hu, 2016, Oncotarget.

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Discovery of a Potent and Selective DDR 1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013 .

Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.

Yan Liu, Feiyang Liu, Peng Gao, 2017, Cancer research.

Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2019, Cancer letters.

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors

Qingsong Liu, X. Liu, X. Xiao, 2019, Therapeutic advances in medical oncology.

Antigen-binding Fragments: Production for and Use in Crystallographic Studies

Feiyang Liu, 2013 .

Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)- N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors.

Zhenquan Hu, Q. Liu, Cheng Chen, 2019, Journal of medicinal chemistry.

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Q. Liu, Hong Wu, Zong-ru Jiang, 2023, Signal Transduction and Targeted Therapy.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

A. Look, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Galactose-imidazole mediated dual-targeting fluorescent probe for detecting Fe3+ in the lysosomes of hepatocytes: Design, synthesis and evaluation.

Jianyi Wang, Mian Wang, Chun-xiao Pu, 2022, Biosensors & bioelectronics.

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R

Kwok-Kin Wong, N. Gray, Qingsong Liu, 2014, Clinical Cancer Research.

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.

Qingsong Liu, Cheng Chen, Ao-li Wang, 2020, Experimental cell research.

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies

Qingsong Liu, J. Griffin, S. Fernandes, 2016, Oncotarget.

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances

Qingsong Liu, J. Griffin, S. Fernandes, 2016, OncoTarget.

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours

Qingsong Liu, Hong Wu, Zong-ru Jiang, 2022, Molecular oncology.

Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2016, Journal of medicinal chemistry.

A Smart Theranostic Prodrug System Activated by Reactive Oxygen Species for Regional Chemotherapy of Metastatic Cancer.

Lingyan Liu, Peng Wei, Wei Yuan, 2022, Angewandte Chemie.

Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding.

Qingsong Liu, Zhenquan Hu, Juan Liu, 2017, Journal of medicinal chemistry.

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML

J. Griffin, E. Weisberg, Zheng Zhao, 2016, Oncotarget.

Discovery of a Highly Selective STK16 Kinase Inhibitor.

N. Gray, Qingsong Liu, Jinhua Wang, 2016, ACS chemical biology.

Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs).

Qingsong Liu, Yuexiang Wang, Zhenquan Hu, 2016, Journal of medicinal chemistry.

Machine learning-based infection prediction model for newly diagnosed multiple myeloma patients

Liang Ding, Ting Peng, Feiyang Liu, 2023, Frontiers in Neuroinformatics.

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies

N. Gray, C. Mitsiades, J. Griffin, 2014, Leukemia.

Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.

N. Gray, Qingsong Liu, C. Benes, 2017, Cancer research.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

N. Gray, Qingsong Liu, W. Hur, 2013, ACS chemical biology.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2016, Journal of medicinal chemistry.

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R

N. Gray, Qingsong Liu, C. Mitsiades, 2014, Clinical Cancer Research.